HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indicate an increased complication rate which might negatively impact the benefit-risk balance of this procedure. In addition, standard treatment with proven efficacy might be withheld due to application of unproven methods. The use of HIPEC outside of well designed, prospective and controlled clinical trials is therefore disregarded.
Die HIPEC wird Patientinnen mit einer durch ein Ovarial-, Tuben-, oder primären Peritonealkarzinom bedingten Peritonealkarzinose an einigen Kliniken angeboten. Insgesamt gibt es jedoch keinen Nachweis, dass bei einem gynäkologischen Tumor durch Einsatz der HIPEC weder in der Primär- noch in der Rezidivsituation eine Verbesserung der Prognose erreicht werden kann. Aufgrund der derzeitigen Datenlage kann durch eine erhöhte Komplikationsrate auch eine Verschlechterung der Prognose nicht ausgeschlossen werden, insbesondere wenn hierdurch den Patientinnen eine erwiesenermaßen wirksame Standardtherapie vorenthalten wird. Daher wird von einer Durchführung der HIPEC außerhalb von prospektiven kontrollierten Studien abgeraten.

Small non-coding RNAs (sRNAs) emerge as exquisite molecules that are guided for transcriptional and posttranscriptional gene regulation in eukaryotes. As one class of most important sRNAs in plants, trans-acting small interfering RNAs (ta-siRNAs) initiate from microRNA (miRNA) - mediated cleavage of TAS gene transcripts and subsequently are stabilized by SUPPRESSOR OF GENE SILENCING3 (SGS3) and converted to double-stranded RNA (dsRNA) by the actions of RNA-DEPENDENT RNA POLYMERASE6 (RDR6). Generally, these dsRNAs are processed by DICER-LIKE4 (DCL4) and recruited into ARGONAUTE 1 (AGO1) complexes to posttranscriptionally regulate target genes by mRNA cleavage in trans. In a recent study, we discovered a non-canonical ta-siRNAs pathway: Starting from the miRNA-guided cleavage site, the dsRNAs are processed by DCL1 into 21-nt siRNAs, which associate with AGO4/6 complexes to direct DNA methylation in cis. Together with previous results that miRNAs can be produced by DCL3, loaded into AGO4 and trigger epigenetically regulation of target genes, these findings indicate much complex biogenesis, effector and action pathways exist in plant sRNAs kingdom.